Bruker Corporation 6.375% Mandatory Convertible Preferred Stock Series A (BRKRP)
Stock · NASDAQ · Industrials
$404.27as of 10/16/2026
Price chart
Active signals
Resistance level
$420.43
Industry
Biotechnology: Laboratory Analytical Instruments
About BRKRP
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle s…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 11,085
- Website
- www.bruker.com/
Fundamentals
- 1-day range
- $403.83$410.26
- Market cap
- $59.91B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.47
- Dividend yield
- 0.30%
- Beta
- 1.24
- Avg. volume
- 6.8K
- Ex-dividend date
- August 14, 2026
- Dividend pay date
- September 1, 2026
52-week range
$32.37$66.98
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock Series A Competitors
Chosen by industry and closest market cap.
- BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock Series A$405.85▼ 2.82%Market cap $59.91BP/E —$32.37$66.98
- AAgilent Technologies Inc. Common Stock$172.97▼ 1.47%Market cap $39.92BP/E 34.26$108.35$177.05
- WATWaters Corporation Common Stock$436.95▼ 1.62%Market cap $39.24BP/E 260.32$282.77$454.54
- MTDMettler-Toledo International Inc. Common Stock$1,622▼ 1.02%Market cap $28.48BP/E 36.08$1,023$1,620
- RVTYRevvity Inc. Common Stock$152.64▼ 1.34%Market cap $12.74BP/E 72.12$81.22$166.25
- BIOBio-Rad Laboratories Inc. Class A Common Stock$353.7▼ 3.05%Market cap $9.16BP/E 43.88$236.73$396.23
- AVTRAvantor Inc. Common Stock$16.42▲ 2.05%Market cap $8.91BP/E —$7.27$16.38
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BRKRP Bruker Corporation 6.375% Mandatory Convertible Preferred Stock Series A | $59.91B | — | $405.85 | ▼ 2.82% | $32.37$66.98 |
| A Agilent Technologies Inc. Common Stock | $39.92B | 34.26 | $172.97 | ▼ 1.47% | $108.35$177.05 |
| WAT Waters Corporation Common Stock | $39.24B | 260.32 | $436.95 | ▼ 1.62% | $282.77$454.54 |
| MTD Mettler-Toledo International Inc. Common Stock | $28.48B | 36.08 | $1,622 | ▼ 1.02% | $1,023$1,620 |
| RVTY Revvity Inc. Common Stock | $12.74B | 72.12 | $152.64 | ▼ 1.34% | $81.22$166.25 |
| BIO Bio-Rad Laboratories Inc. Class A Common Stock | $9.16B | 43.88 | $353.7 | ▼ 3.05% | $236.73$396.23 |
| AVTR Avantor Inc. Common Stock | $8.91B | — | $16.42 | ▲ 2.05% | $7.27$16.38 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Is Bruker (BRKR) Getting Attention For Its Human Plasma Proteome Atlas?Yahoo · 10/9/2026
- Bruker (BRKR), Why Is Its Latest Update Drawing Fresh Attention?Yahoo · 10/8/2026
- Bruker Gains 66.3% in a Year: What's Driving the Rally?Yahoo · 10/8/2026
- 3 Cash-Producing Stocks We Steer Clear OfYahoo · 10/7/2026
- Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform ResolutionYahoo · 10/6/2026
- Are Options Traders Betting on a Big Move in Bruker Stock?Yahoo · 10/5/2026
- 1 Surging Stock to Target This Week and 2 We QuestionYahoo · 10/5/2026
- QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared PanelYahoo · 10/2/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BRKRP (Bruker) faces risk concerns amid plasma atlas buzz
Recent coverage highlights risk factors for Bruker, including concerns about its convertible preferred shares and broader company outlook. At the same time, new attention focuses on Bruker's Human Plasma Proteome Atlas, which draws interest from researchers. These news items together influence sentiment around BRKRP, the preferred series, as investors weigh the risks and scientific developments.
BRKRP (Bruker) faces risk concerns amid plasma atlas buzz. Recent coverage highlights risk factors for Bruker, including concerns about its convertible preferred shares and broader company outlook. At the same time, new attention focuses on Bruker's Human Plasma Proteome Atlas, which draws interest from researchers. These news items together influence sentiment around BRKRP, the preferred series, as investors weigh the risks and scientific developments.